GlassScriptPhysician profile
John S Michel
NPI 1164697124
$22,667.91
in general payments reported to CMS, 2019-2025
69 companies · $1,657 in 2025
The $1,657 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,470 · 2020: $2,965 · 2021: $3,824 · 2022: $3,351 · 2023: $3,874 · 2024: $4,527 · 2025: $1,657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,902 · Education: $156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,902.16 |
| Education | $156.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,449.63 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $1,889.00 | 2019-2025 | Breztri, Farxiga, Fasenra |
| Abbvie INC. | $1,575.71 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $1,495.37 | 2019-2024 | Xarelto, Invega Trinza, Invega Sustenna |
| Gilead Sciences, INC. | $977.33 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $877.86 | 2019-2025 | Austedo, Austedo Xr, Austedo Xr |
| Novo Nordisk INC | $811.90 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $739.11 | 2019-2025 | Mounjaro, Zepbound, Amyvid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $715.21 | 2019-2025 | Jardiance, Synjardy |
| Pfizer INC. | $707.35 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $686.04 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $625.01 | 2019-2023 | Verquvo, Belsomra |
| Astellas Pharma US INC | $589.03 | 2019-2024 | Veozah, Myrbetriq |
| E.R. Squibb & Sons, L.L.C. | $521.88 | 2021-2025 | Eliquis, Camzyos, Cobenfy |
| Ucb, INC. | $478.47 | 2021-2024 | Briviact, Nayzilam |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Michel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.